Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- The Management of Chronic Liver Disease, Including Transplantation
- Outline (3)
- Liver allocation
- Mortality risk according to MELD
- Liver transplant surgery
- Outline (4)
- Biliary complications
- Anastomotic stricture
- Biliary leakage
- Biliary cast
- GI related disorders
- Inflammatory bowel disease
- Obesity
- Bone disease
- Bone disease recommendations
- Cardiovascular
- Cardiovascular recommendations
- Diabetes
- Renal disease
- De novo malignancy
- De novo malignancies OLT
- Annual examinations
- Vaccine
- Common drug interactions
- Next decade?
Topics Covered
- Listing criteria for liver transplantation
- Management of common medical conditions after liver transplantation
- GI related disorders
- Bone disease risk
- Cardiovascular risk
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
McCashland, T.M. (2021, September 30). The management of chronic liver disease, including transplantation 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 30, 2024, from https://doi.org/10.69645/BEFL5568.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Timothy M. McCashland has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
The management of chronic liver disease, including transplantation 2
Published on September 30, 2021
21 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:03
We'll move on to listing for liver transplantation.
0:09
Currently, there is no uniform organ allocation system within the world or countries,
it is usually center-driven.
However, in the United States, it is driven by the government, to where currently,
the allocation system has evolved from the model for end-stage liver disease
to MELD with sodium.
This is a status system, where the highest scorer on the MELD score is
the individual who is chosen as the recipient for liver transplantation.
MELD exception points are now under the national review board,
rather than regional review boards.
Each center will be allocated a mean MELD score at that center, minus their three points.
Donation for transplantation includes donation after brain death,
donation after circulatory death (DCD donors), and living donation (liver donation).
Extended donor criteria include those individuals who are older than 65,
who have marked steatosis within the graft, who have a DCD donor,
if the donor has an infection at time of transplantation donation,
some specific neurologic tumors, and high-risk behaviors, such as those individuals
who have opiate addictions and IV drug use.